Warren Stone Elevated to President and COO at NeoGenomics; Leadership Restructuring Signals Operational Focus

NeoGenomics, Inc. (NASDAQ: NEO), a prominent player in oncology diagnostic solutions for precision medicine, has announced a significant leadership transition. The company is promoting Warren Stone from Chief Commercial Officer to President and Chief Operating Officer, a move set to take effect on April 1, 2025. This appointment reflects the organization’s strategic emphasis on integrating commercial growth with operational excellence.

Leadership Changes Drive Strategic Alignment

The restructuring involves the departure of Melody Harris, the current Chief Operations Officer, who will leave NeoGenomics at the end of May. Stone’s expanded mandate encompasses lab operations, the data solutions division, and enterprise operations functions, while he retains oversight of the commercial portfolio—spanning clinical services, pharmaceutical partnerships, marketing, product management, and customer success programs.

Stone brings over 25 years of cross-functional management experience to the role. Since joining NeoGenomics in November 2022, his tenure as Chief Commercial Officer—a position he assumed in April 2024—has coincided with measurable commercial momentum. The Clinical division has achieved eight consecutive quarters of double-digit revenue expansion, positioning NeoGenomics as a competitive force in the oncology marketplace.

Operational Expansion and Commercial Synergy

Beth Eastland, Senior Vice President of Enterprise Sales, will assume day-to-day leadership of all enterprise sales operations and support Stone in his new capacity. Eastland arrived at NeoGenomics in 2024 following an extensive career at a leading oncology diagnostics organization, where she accumulated over 35 years of healthcare commercial expertise.

The organizational restructuring aims to enhance agility by merging commercial and operations functions under unified leadership. This integration is intended to amplify the company’s ability to leverage its diagnostic portfolio and sales channels while maintaining focus on research and development and strategic business development initiatives.

Background on Stone’s Career Trajectory

Stone’s professional journey reflects deep experience in diagnostics and healthcare. Prior to joining NeoGenomics, he served as President of the Americas at Ortho Clinical Diagnostics and held a Senior Vice President role at MilliporeSigma. His educational credentials include an MBA from Suffolk University and a BASc in analytical chemistry from Technikon Witwatersrand, South Africa.

About NeoGenomics

NeoGenomics, Inc. operates as a specialized cancer diagnostics enterprise, offering comprehensive oncology-focused testing throughout the disease continuum. The company serves oncologists, pathologists, hospital networks, academic institutions, and pharmaceutical organizations with advanced diagnostic and predictive testing capabilities. Headquartered in Fort Myers, Florida, NeoGenomics maintains a network of CAP-accredited and CLIA-certified laboratories across the United States and operates a full-service sample-processing facility in Cambridge, United Kingdom.